Reach Us +44-1647-403003
Breast Cancer In Elderly Patients (70 Years And Older): The University Of Tennessee Medical Center At Knoxville 10 Year Experience | 33650
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience

World Congress on Breast Cancer

Matthew Curzon

The University of Tennessee Medical Center, USA

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956.S1.041

Breast cancer (BC) incidence increases with age; however, there is still a paucity of data on cancer biology, standardized treatment, and outcomes in elderly (≥70 y/o) patients. We evaluated whether ER/PR/HER2 subtype and TNM stage of invasive BC had significant impact on overall survival (OS) in a study population of 232 elderly Caucasian female patients (≥70 y/o) from our institution at the 10 year interval (01/1998-7/2008), and analyzed treatments that they received (last follow-up date 8/1/2013). Patients were grouped according to TNM stage and ER/PR/HER2 subtype using 5-group classification system per 2011 St. Gallen International Consensus Panel recommendations. OS was measured comparing these categories using Kaplan Meier curves and Cox regression analysis. The majority of patients (178/232=76.7%) were in the traditionally considered “favorable” BC subtype (ER+/PR+/HER2-); 23.3% were in “unfavorable” subtype [HER2+=12% (28/232) and triple negative (TNP) =11.3% (26/232)]. Interestingly, a trend for better survival was noted in HER2+ patients, the group that is only nowadays considered worth reclassifying to “favorable” due to advantageous effects of anti-HER2 treatment (HER2+ OS=68%; ER+/PR+/ HER2- OS=56% and TNP OS=58%). However, no ER/PR/HER2 subtype was significantly predictive of better OS (p=.73). TNM stage was predictive of OS (p<0.001). Our previously published data on non-significant effects of ER/PR/HER2 on OS in our Caucasian BC patient population are concordanttoresults obtained in our elderly patient subgroup. Discussion of this abstract will include the treatments that our patients received and compare/contrast them to the literature data in an attempt to reconcile and stratify given therapy with outcomes.

Matthew Curzon received a BSc degree in Physiological Science from the University of California, Los Angeles in 2008 and his Medical degree from the American University of the Caribbean in 2012. Currently, he is a Chief Resident and a PGY-3 resident in Anatomic and Clinical Pathology Residency Program at the University of Tennessee Medical Center in Knoxville, Tennessee. He has research interest in breast cancer, biomarkers and improving patient outcomes.

Relevant Topics